Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug acoramidis tested for Long-Term cardiac repair in rare amyloidosis

NCT ID NCT07695701

Not yet recruiting Disease control Sponsor: Eidos Therapeutics, a BridgeBio company Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests the drug acoramidis in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart, weakening it. Over 36 months, researchers measure whether acoramidis improves heart function and structure using cardiac MRI. Participants take the drug twice daily, and the goal is to see if the heart can pump blood more effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
acoramidis (AG10) oral tablet
What this could lead to
If successful, this could show that acoramidis helps stabilize or improve heart function in people with ATTR-CM, potentially slowing disease progression.
What could go wrong
This is an open-label study without a placebo group, so results may be less definitive. The drug may not improve heart function for all participants, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Amyloid Neuropathies, Familial amyloidosis cardiomyopathy familial amyloid neuropathy restrictive cardiomyopathy wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYLOID CARDIOMYOPATHY AMYLOIDOSIS TRANSTHYRETIN AMYLOIDOSIS TRANSTHYRETIN AMYLOIDOSIS CARDIOMYOPATHY (ATTR-CM)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.